Translational Mini‐Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell‐targeted therapies
Summary OTHER ARTICLES PUBLISHED IN THIS MINI‐REVIEW SERIES ON B CELL SUBSETS IN DISEASE B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein—Barr virus entry to the central nervous system? Clinical and Experimental Immunology 2012, 167: 1–6. Reconstitution aft...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental immunology 2012-01, Vol.167 (1), p.7-14 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 1 |
| container_start_page | 7 |
| container_title | Clinical and experimental immunology |
| container_volume | 167 |
| creator | Vossenkämper, A. Lutalo, P. M. K. Spencer, J. |
| description | Summary
OTHER ARTICLES PUBLISHED IN THIS MINI‐REVIEW SERIES ON B CELL SUBSETS IN DISEASE
B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein—Barr virus entry to the central nervous system? Clinical and Experimental Immunology 2012, 167: 1–6. Reconstitution after haematopoietic stem cell transplantation – revelation of B cell developmental pathways and lineage phenotypes. Clinical and Experimental Immunology 2012, 167: 15–25.
Systemic lupus erythematosus (SLE) and Sjögren's syndrome are autoimmune disorders which are characterized by a disturbed B cell homeostasis which leads ultimately to dysfunction of various organs. One of the B cell subsets that appear in abnormal numbers is the population of transitional B cells, which is increased in the blood of patients with SLE and Sjögren's syndrome. Transitional B cells are newly formed B cells. In mice, transitional B cells undergo selection checks for unwanted specificity in the bone marrow and the spleen in order to eliminate autoreactive B cells from the circulating naive B cell population. In humans, the exact anatomical compartments and mechanisms of the specificity check‐points for transitional B cells remain unclear, but appear to be defective in SLE and Sjögren's syndrome. This review aims to highlight the current understanding of transitional B cells and their defects in the two disorders before and after B cell‐targeted therapies. |
| doi_str_mv | 10.1111/j.1365-2249.2011.04460.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3248081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>908011515</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5630-52da9fcd2821b55d78f4e4f166377a006e0e6649410bbddb1fcb54a7d87e647c3</originalsourceid><addsrcrecordid>eNqNkl1u1DAUhSMEoqWwBWQJoT5NsB3bSZBAglGBSkVItDxbjnMz9SiJB9-k7byxBFbDBlgAe2AlODPD8PMCfrEtf_f4XPskCWE0ZXE8WaYsU3LGuShTThlLqRCKpje3ksP9we3kkFJazkpGxUFyD3EZt0opfjc54JxlvMjLw-TbRTA9tmZwvjcteet69_3T5_dw5eCanENwgMT35CWx0LYExwphQOJ6UjsEg5CSjYDb1W-5DYBrHKBzlrTjakQCYT1cQmcGj3Fn-pqcL79-WQTojzGyfR18B0-JbaMDG5Vct2rjYtLd4tA0YOPdvtndEn0OJixggJpE6WBW0ez95E5jWoQHu_ko-fDq5GL-Znb27vXp_MXZzEqV0ZnktSkbW_OCs0rKOi8aAaJhSmV5buI7AQWlRCkYraq6rlhjKylMXhc5KJHb7Ch5vtVdjVUHtYV-CKbVq-A6E9baG6f_POndpV74K51xUdCCRYHjnUDwH0fAQXcOp7ZMD35EXTIpCpUz9W-SFjECkslIPvqLXPoxxH9BHdVkobJSFpEqtpQNHjFAs3fNqJ7ipZd6SpGeUqSneOlNvPRNLH34e9f7wp95isDjHWAw_mITs2Ed_uIkjz6yqadnW-7atbD-bwN6fnI6rbIfShLyww</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1545863958</pqid></control><display><type>article</type><title>Translational Mini‐Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell‐targeted therapies</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Vossenkämper, A. ; Lutalo, P. M. K. ; Spencer, J.</creator><creatorcontrib>Vossenkämper, A. ; Lutalo, P. M. K. ; Spencer, J.</creatorcontrib><description>Summary
OTHER ARTICLES PUBLISHED IN THIS MINI‐REVIEW SERIES ON B CELL SUBSETS IN DISEASE
B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein—Barr virus entry to the central nervous system? Clinical and Experimental Immunology 2012, 167: 1–6. Reconstitution after haematopoietic stem cell transplantation – revelation of B cell developmental pathways and lineage phenotypes. Clinical and Experimental Immunology 2012, 167: 15–25.
Systemic lupus erythematosus (SLE) and Sjögren's syndrome are autoimmune disorders which are characterized by a disturbed B cell homeostasis which leads ultimately to dysfunction of various organs. One of the B cell subsets that appear in abnormal numbers is the population of transitional B cells, which is increased in the blood of patients with SLE and Sjögren's syndrome. Transitional B cells are newly formed B cells. In mice, transitional B cells undergo selection checks for unwanted specificity in the bone marrow and the spleen in order to eliminate autoreactive B cells from the circulating naive B cell population. In humans, the exact anatomical compartments and mechanisms of the specificity check‐points for transitional B cells remain unclear, but appear to be defective in SLE and Sjögren's syndrome. This review aims to highlight the current understanding of transitional B cells and their defects in the two disorders before and after B cell‐targeted therapies.</description><identifier>ISSN: 0009-9104</identifier><identifier>EISSN: 1365-2249</identifier><identifier>DOI: 10.1111/j.1365-2249.2011.04460.x</identifier><identifier>PMID: 22132879</identifier><identifier>CODEN: CEXIAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Analytical, structural and metabolic biochemistry ; Animals ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antibodies, Monoclonal, Murine-Derived - therapeutic use ; B-Cell Activating Factor - immunology ; B-Lymphocyte Subsets - immunology ; B-Lymphocyte Subsets - pathology ; belimumab ; Biological and medical sciences ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Disease Models, Animal ; Double-Blind Method ; Epstein-Barr virus ; Fundamental and applied biological sciences. Psychology ; Humans ; Lupus Erythematosus, Systemic - immunology ; Lupus Erythematosus, Systemic - pathology ; Lupus Erythematosus, Systemic - therapy ; Lymphocyte Count ; Lymphocyte Depletion - methods ; Lymphoid Tissue - immunology ; Lymphoid Tissue - pathology ; Lymphopoiesis ; Medical sciences ; Mice ; Review ; Rituximab ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Sjogren's Syndrome - immunology ; Sjogren's Syndrome - pathology ; Sjogren's Syndrome - therapy ; systemic lupus erythematosus ; transitional B cells</subject><ispartof>Clinical and experimental immunology, 2012-01, Vol.167 (1), p.7-14</ispartof><rights>2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology</rights><rights>2015 INIST-CNRS</rights><rights>2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.</rights><rights>Copyright © 2012 British Society for Immunology 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5630-52da9fcd2821b55d78f4e4f166377a006e0e6649410bbddb1fcb54a7d87e647c3</citedby><cites>FETCH-LOGICAL-c5630-52da9fcd2821b55d78f4e4f166377a006e0e6649410bbddb1fcb54a7d87e647c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248081/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248081/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25254536$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22132879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vossenkämper, A.</creatorcontrib><creatorcontrib>Lutalo, P. M. K.</creatorcontrib><creatorcontrib>Spencer, J.</creatorcontrib><title>Translational Mini‐Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell‐targeted therapies</title><title>Clinical and experimental immunology</title><addtitle>Clin Exp Immunol</addtitle><description>Summary
OTHER ARTICLES PUBLISHED IN THIS MINI‐REVIEW SERIES ON B CELL SUBSETS IN DISEASE
B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein—Barr virus entry to the central nervous system? Clinical and Experimental Immunology 2012, 167: 1–6. Reconstitution after haematopoietic stem cell transplantation – revelation of B cell developmental pathways and lineage phenotypes. Clinical and Experimental Immunology 2012, 167: 15–25.
Systemic lupus erythematosus (SLE) and Sjögren's syndrome are autoimmune disorders which are characterized by a disturbed B cell homeostasis which leads ultimately to dysfunction of various organs. One of the B cell subsets that appear in abnormal numbers is the population of transitional B cells, which is increased in the blood of patients with SLE and Sjögren's syndrome. Transitional B cells are newly formed B cells. In mice, transitional B cells undergo selection checks for unwanted specificity in the bone marrow and the spleen in order to eliminate autoreactive B cells from the circulating naive B cell population. In humans, the exact anatomical compartments and mechanisms of the specificity check‐points for transitional B cells remain unclear, but appear to be defective in SLE and Sjögren's syndrome. This review aims to highlight the current understanding of transitional B cells and their defects in the two disorders before and after B cell‐targeted therapies.</description><subject>Analytical, structural and metabolic biochemistry</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>B-Cell Activating Factor - immunology</subject><subject>B-Lymphocyte Subsets - immunology</subject><subject>B-Lymphocyte Subsets - pathology</subject><subject>belimumab</subject><subject>Biological and medical sciences</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Disease Models, Animal</subject><subject>Double-Blind Method</subject><subject>Epstein-Barr virus</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Humans</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Lupus Erythematosus, Systemic - pathology</subject><subject>Lupus Erythematosus, Systemic - therapy</subject><subject>Lymphocyte Count</subject><subject>Lymphocyte Depletion - methods</subject><subject>Lymphoid Tissue - immunology</subject><subject>Lymphoid Tissue - pathology</subject><subject>Lymphopoiesis</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Review</subject><subject>Rituximab</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Sjogren's Syndrome - immunology</subject><subject>Sjogren's Syndrome - pathology</subject><subject>Sjogren's Syndrome - therapy</subject><subject>systemic lupus erythematosus</subject><subject>transitional B cells</subject><issn>0009-9104</issn><issn>1365-2249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl1u1DAUhSMEoqWwBWQJoT5NsB3bSZBAglGBSkVItDxbjnMz9SiJB9-k7byxBFbDBlgAe2AlODPD8PMCfrEtf_f4XPskCWE0ZXE8WaYsU3LGuShTThlLqRCKpje3ksP9we3kkFJazkpGxUFyD3EZt0opfjc54JxlvMjLw-TbRTA9tmZwvjcteet69_3T5_dw5eCanENwgMT35CWx0LYExwphQOJ6UjsEg5CSjYDb1W-5DYBrHKBzlrTjakQCYT1cQmcGj3Fn-pqcL79-WQTojzGyfR18B0-JbaMDG5Vct2rjYtLd4tA0YOPdvtndEn0OJixggJpE6WBW0ez95E5jWoQHu_ko-fDq5GL-Znb27vXp_MXZzEqV0ZnktSkbW_OCs0rKOi8aAaJhSmV5buI7AQWlRCkYraq6rlhjKylMXhc5KJHb7Ch5vtVdjVUHtYV-CKbVq-A6E9baG6f_POndpV74K51xUdCCRYHjnUDwH0fAQXcOp7ZMD35EXTIpCpUz9W-SFjECkslIPvqLXPoxxH9BHdVkobJSFpEqtpQNHjFAs3fNqJ7ipZd6SpGeUqSneOlNvPRNLH34e9f7wp95isDjHWAw_mITs2Ed_uIkjz6yqadnW-7atbD-bwN6fnI6rbIfShLyww</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Vossenkämper, A.</creator><creator>Lutalo, P. M. K.</creator><creator>Spencer, J.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Oxford University Press</general><general>Blackwell Science Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201201</creationdate><title>Translational Mini‐Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell‐targeted therapies</title><author>Vossenkämper, A. ; Lutalo, P. M. K. ; Spencer, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5630-52da9fcd2821b55d78f4e4f166377a006e0e6649410bbddb1fcb54a7d87e647c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Analytical, structural and metabolic biochemistry</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>B-Cell Activating Factor - immunology</topic><topic>B-Lymphocyte Subsets - immunology</topic><topic>B-Lymphocyte Subsets - pathology</topic><topic>belimumab</topic><topic>Biological and medical sciences</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Disease Models, Animal</topic><topic>Double-Blind Method</topic><topic>Epstein-Barr virus</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Humans</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Lupus Erythematosus, Systemic - pathology</topic><topic>Lupus Erythematosus, Systemic - therapy</topic><topic>Lymphocyte Count</topic><topic>Lymphocyte Depletion - methods</topic><topic>Lymphoid Tissue - immunology</topic><topic>Lymphoid Tissue - pathology</topic><topic>Lymphopoiesis</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Review</topic><topic>Rituximab</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Sjogren's Syndrome - immunology</topic><topic>Sjogren's Syndrome - pathology</topic><topic>Sjogren's Syndrome - therapy</topic><topic>systemic lupus erythematosus</topic><topic>transitional B cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vossenkämper, A.</creatorcontrib><creatorcontrib>Lutalo, P. M. K.</creatorcontrib><creatorcontrib>Spencer, J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and experimental immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vossenkämper, A.</au><au>Lutalo, P. M. K.</au><au>Spencer, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Translational Mini‐Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell‐targeted therapies</atitle><jtitle>Clinical and experimental immunology</jtitle><addtitle>Clin Exp Immunol</addtitle><date>2012-01</date><risdate>2012</risdate><volume>167</volume><issue>1</issue><spage>7</spage><epage>14</epage><pages>7-14</pages><issn>0009-9104</issn><eissn>1365-2249</eissn><coden>CEXIAL</coden><abstract>Summary
OTHER ARTICLES PUBLISHED IN THIS MINI‐REVIEW SERIES ON B CELL SUBSETS IN DISEASE
B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein—Barr virus entry to the central nervous system? Clinical and Experimental Immunology 2012, 167: 1–6. Reconstitution after haematopoietic stem cell transplantation – revelation of B cell developmental pathways and lineage phenotypes. Clinical and Experimental Immunology 2012, 167: 15–25.
Systemic lupus erythematosus (SLE) and Sjögren's syndrome are autoimmune disorders which are characterized by a disturbed B cell homeostasis which leads ultimately to dysfunction of various organs. One of the B cell subsets that appear in abnormal numbers is the population of transitional B cells, which is increased in the blood of patients with SLE and Sjögren's syndrome. Transitional B cells are newly formed B cells. In mice, transitional B cells undergo selection checks for unwanted specificity in the bone marrow and the spleen in order to eliminate autoreactive B cells from the circulating naive B cell population. In humans, the exact anatomical compartments and mechanisms of the specificity check‐points for transitional B cells remain unclear, but appear to be defective in SLE and Sjögren's syndrome. This review aims to highlight the current understanding of transitional B cells and their defects in the two disorders before and after B cell‐targeted therapies.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22132879</pmid><doi>10.1111/j.1365-2249.2011.04460.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9104 |
| ispartof | Clinical and experimental immunology, 2012-01, Vol.167 (1), p.7-14 |
| issn | 0009-9104 1365-2249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3248081 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Analytical, structural and metabolic biochemistry Animals Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Monoclonal, Murine-Derived - therapeutic use B-Cell Activating Factor - immunology B-Lymphocyte Subsets - immunology B-Lymphocyte Subsets - pathology belimumab Biological and medical sciences Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Disease Models, Animal Double-Blind Method Epstein-Barr virus Fundamental and applied biological sciences. Psychology Humans Lupus Erythematosus, Systemic - immunology Lupus Erythematosus, Systemic - pathology Lupus Erythematosus, Systemic - therapy Lymphocyte Count Lymphocyte Depletion - methods Lymphoid Tissue - immunology Lymphoid Tissue - pathology Lymphopoiesis Medical sciences Mice Review Rituximab Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Sjogren's Syndrome - immunology Sjogren's Syndrome - pathology Sjogren's Syndrome - therapy systemic lupus erythematosus transitional B cells |
| title | Translational Mini‐Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell‐targeted therapies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T07%3A23%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Translational%20Mini%E2%80%90Review%20Series%20on%20B%20cell%20subsets%20in%20disease.%20Transitional%20B%20cells%20in%20systemic%20lupus%20erythematosus%20and%20Sj%C3%B6gren's%20syndrome:%20clinical%20implications%20and%20effects%20of%20B%20cell%E2%80%90targeted%20therapies&rft.jtitle=Clinical%20and%20experimental%20immunology&rft.au=Vossenk%C3%A4mper,%20A.&rft.date=2012-01&rft.volume=167&rft.issue=1&rft.spage=7&rft.epage=14&rft.pages=7-14&rft.issn=0009-9104&rft.eissn=1365-2249&rft.coden=CEXIAL&rft_id=info:doi/10.1111/j.1365-2249.2011.04460.x&rft_dat=%3Cproquest_pubme%3E908011515%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1545863958&rft_id=info:pmid/22132879&rfr_iscdi=true |